It operates in the world of health and science. It has 1 employee. Now — the numbers.
This is an established company with proven profits.
The gap is $1.4M. In times of high interest rates, a gap like that can squeeze a company.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.04. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 12 months, executives reported 6 sells against just 0 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, WENAW sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: WENAW is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.